Pharmacologic treatments for covid-19 patients

Vilobelimab vs Placebo/Standard care


Hospitalized patients

Forest plots
(last update: 2022-10-14)

Summary of findings
(last update: 2022-10-17)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=1018

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04333420, EudraCT 2020-001335-28
PANAMO
Vlaar APJ, Lancet Respir Med, 2022
Full text
Commentary
Commentary
Mixed

Vilobelimab

Placebo

RCT Patients with confirmed COVID-19 (critical) admitted to 46 centers in the Netherlands, Brazil, Mexico, France, Russia, Germany, Belgium, Peru, and South Africa. N=369
Some concerns
Details

Full description

NCT04333420
PANAMO
Vlaar APJ, Lancet Rheumatol, 2020
Full text
Commentary
Private

Vilobelimab

Standard care

RCT Patients with confirmed COVID-19 (moderate-critical) admitted to three centers N=30
Some concerns
Details

Full description